STAT1d
Despite setback, AbbVie’s big bet on neuroscience has yet to play out
For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
What Most People Get Wrong About Schizophrenia
The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...
Psychedelics Like Psilocybin, MDMA Tied to Higher Odds for Schizophrenia
Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...
MedPage Today2d
Magnetic Stimulation Reduced Auditory Hallucinations in Patients With Schizophrenia
For patients with schizophrenia, repetitive transcranial magnetic stimulation (rTMS) was effective and safe in treating ...
Stocktwits on MSN2d
Bristol-Myers Hits 14-Month High After AbbVie’s Schizophrenia Drug Fails, Boosting Retail Sentiment
Bristol Myers Squibb ($BMY) stock rocketed over 11% in early morning trading on Monday to hit a 14-month high of $61.08 after ...
S&P 500 Gains and Losses Today: Index Closes Above 6,000 on Post-Election Rally
The S&P 500 added 0.1% on Monday, Nov. 11, 2024, closing above the 6,000-point milestone as investors continued to weigh the ...
Why AbbVie Stock Was Getting Mashed on Monday
Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs ...
Seeking Alpha2d
AbbVie Stock: Keep Calm And Buy The Dip
Dividend yield and robust drug pipeline are bullish going forward. AbbVie (NYSE:ABBV) shares are plummeting as the company's ...